'Vaccination drive is going on smoothly. It will get more accelerated in the coming days with the ramping up of production by four more Indian companies,' said Union Health Minister Mansukh Mandaviya
Serum Institute of India’s Covishield has not received the EU Covid-19 Vaccination Passport due to which those vaccinated with Covishield will not be able to travel across the EU
Taking to Twitter, SII CEO said, 'Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune.'
While Covishield has an emergency use listing from the WHO, it is yet to receive a similar approval from the European Union.
The travellers vaccinated with Covishield may not be eligible for the European Union ‘Green Pass’- an immunity document that is meant to ease travel
Covid Explained: The new vaccine shall be launched under the brand name of Covovax, which SII is manufacturing in partnership with Novovax.
Serum Institute of India’s Covishield has not received the EU Covid-19 Vaccination Passport due to which those vaccinated with Covishield will not be able to travel across the EU
Serum Institute of India has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V at its licensed Hadapsar facility.
Stating that its employees have been working round the clock, Serum Institute of India said it has ‘always been sincerely concerned about the protection of...
In a letter to the Union Health Ministry on May 22, Serum Institute clarified that the statement by its executive director Suresh Jadav at a recent event is...
Who advised the government to extend the Covid vaccination drive to all adults without considering supplies?
Despite knowing well that vaccines are not available in the country, the Centre widened the Covid inoculation drive without considering WHO guideline, Serum...
.png)
Serum continues to scale up manufacturing and prioritise India. It also hopes to start delivering (vaccines) to COVAX and other countries by end of this year,...
As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share, taking the total deal value to Rs 118.02...
The decision comes in the wake of widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.
Making the announcement, Union government officials said the aim of the move was to protect the Pune-based businessman from 'potential threats'
Serum Institute of India (SII) in a statement clarified that there was an 'inaccurate comparison' done between the global prices of the vaccine with India.
A BJP member says putting some responsibility on the states may help BJP save some political dividend.
This comes ahead of the new round of vaccinations from May 1 that will include all above 18.
Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, Adar Poonawalla...
Once the results of clinical trials are available, another series of steps are required, to investigate the efficacy and safety, before a vaccine may be...
_570_850.png)
Cutis-Biotech, a pharmaceutical firm, filed a suit claiming it was a prior user of the brand name—‘Covishield’, and sought to restrain Serum Institute of...
Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said his company has applied to start the trials of another COVID-19 vaccine
The building where the fire broke out is one km from the Covishield vaccine manufacturing
Scientists at work to churn out millions of Covid-19 vaccine doses inside the laboratories of Serum Institute of India
